Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo.
Nair
R V
RV
Department of Cardiothoracic Surgery, Stanford University School of Medicine, California, USA.
Huang
X
X
Shorthouse
R
R
Adams
B
B
Brazelton
T
T
Braun-Dullaeus
R
R
Morris
R E
RE
D000328:Adult; D001989:Bronchiolitis Obliterans / Q000188:drug therapy / Q000517:prevention & control*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004247:DNA / Q000096:biosynthesis; D005347:Fibroblasts; D006084:Graft Rejection / Q000188:drug therapy / Q000517:prevention & control*; D006133:Growth Substances / Q000494:pharmacology*; D016041:Heart-Lung Transplantation / Q000276:immunology / Q000473:pathology / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008168:Lung / Q000166:cytology* / Q000187:drug effects; D016040:Lung Transplantation / Q000276:immunology / Q000473:pathology / Q000502:physiology*; D011090:Polyenes / Q000494:pharmacology*; D020123:Sirolimus; D014184:Transplantation, Homologous
D006133:Growth Substances; D007166:Immunosuppressive Agents; D011090:Polyenes; D004247:DNA; D020123:Sirolimus